Augmenix

Augmenix is a medical technology company that develops proprietary absorbable PEG hydrogels that separate and protect organs at risk during radiotherapy. The SpaceOAR® hydrogel provides a barrier between the prostate and rectum to decrease rectal toxicity and minimize changes in quality of life (QOL) following prostate radiotherapy. The 3-year follow-up study results of a Phase 3 clinical trial demonstrated a significant reduction in late rectal toxicity (78%) along with favorable bowel, urinary and sexual QOL measurements. The spacer is placed via a transperineal injection of liquid hydrogel precursors between Denonvilliers’ fascia and the anterior rectal wall. There the liquid expands the potential space and then solidifies, forming an absorbable hydrogel spacer. The procedure can be performed in the outpatient setting under local anesthesia and is reimbursed under CPT® code 55874. SpaceOAR System is FDA cleared, CE marked, approved in Australia and Japan and licensed in Canada

201 Burlington Road
Lower Level
Bedford, MA 01730
(781) 902-1625
http://www.augmenix.com/

BrachytherapyMedical Device and EquipmentRadiation Protection/ShieldingRadiation Therapy